



ABN 53 075 582 740

ASX ANNOUNCEMENT

30 April 2018

Quarterly Cashflow Report

Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a global, clinical stage biopharmaceutical company, today released its Appendix 4C - Quarterly Cashflow Report.

During the quarter, Bionomics has progressed both its development pipeline of innovative therapies and its business objectives.

Recent BNC210 presentations have highlighted the ongoing Phase 2 trial of BNC210 in patients with Post-Traumatic Stress Disorder (PTSD) and data supporting its potential as a therapy for anxiety disorders, depressive conditions with co-morbid anxiety, agitation, stress and trauma related disorders.

- On 11 April 2018, Bionomics announced that the RESTORE trial, a Phase 2 clinical trial designed to evaluate the safety and efficacy of BNC210 for the treatment of PTSD, is fully recruited. BNC210 is a novel, first-in-class, negative allosteric modulator of the $\alpha 7$ nicotinic acetylcholine receptor. Full recruitment in the RESTORE trial marks a significant achievement for Bionomics and topline data from this study is anticipated in the second half of CY2018.
- The RESTORE trial is a randomized, double-blind, placebo-controlled Phase 2 clinical trial designed to enrol up to 192 adult patients diagnosed with PTSD at sites across the United States and Australia. The primary endpoint of this study is a decrease in PTSD symptoms as measured by the Clinician-Administered PTSD Scale (CAPS-5). Secondary endpoints include a decrease in symptoms of anxiety as measured by the Hamilton Anxiety Rating Scale (HAM-A) and symptoms of depression as measured by the Montgomery and Asberg Depression Rating Scale (MADRS).
- On 13 April 2018 in New York and 17 April 2018 in London, Bionomics hosted two Key Opinion Leader events focused on the potential of BNC210 to treat PTSD.
- The New York event featured a presentation by Murray B. Stein, MD, MPH, FRCPC, Distinguished Professor of Psychiatry and Family Medicine & Public Health, and Vice Chair for Clinical Research in Psychiatry at the University of California San Diego (UCSD). Dr Stein is also a Staff Psychiatrist at the VA San Diego Healthcare System where he treats individuals with anxiety, and trauma and stressor-related disorders, including PTSD.
- The London event was co-chaired by Professor Allan Young, MB ChB, MPhil, PhD, FRCPsych, FRCPC, FRSB., Director of the Centre for Affective Disorders in the Department of Psychological Medicine at King's College London. Professor Young was the Principal Investigator for the positive trial of BNC210 in Generalised Anxiety Disorder (GAD) patients.

Whilst BNC210, Bionomics' proprietary ionX drug discovery platform and our important relationship with Merck & Co., (known as MSD outside the US and Canada) are the primary focus of the Company, Bionomics' clinical stage oncology assets delivered new data during the quarter.

- On 16-17 April 2018 in Chicago, Bionomics presented data at the American Association for Cancer Research on BNC101 and BNC105. The presentations were entitled:
 - *Characterization of BNC101 a humanized monoclonal antibody targeting the GPCR LGR5: First in human evidence of target engagement.*
 - *The microtubulin-disrupting drug BNC105 is a potent inducer of apoptosis in AML patient samples.* BNC105 was shown to be more potent than competing products in development.
- Bionomics is currently undertaking a formal process to monetise through divestment and/or out-licensing both BNC101 and BNC105 as the company completes its transition to a focused Central Nervous System (CNS) disorders company. These new data are anticipated to assist that process.

Bionomics is in a strong position to fund its current development programs.

- Cash balance at 31 March 2018 was \$32.254m (31 December 2017: \$32.021m) with net operating cash inflow during the quarter ended 31 March 2018 of \$0.158m.
- Cash receipts for the period included receipts from customers totalling \$0.900m for the current quarter ending 31 March 2018. Bionomics received an R&D Tax Incentive refund of \$6.788m in January 2018.
- Cash outflow reflected investment in the ongoing Phase 2 clinical trial of BNC210 in PTSD and the BNC101 Phase 1 clinical trial in patients with metastatic colon cancer.

Whilst section 9 of the Appendix 4C shows the estimated cash outflows for the next quarter, no estimated cash inflows are provided. The estimated cash outflows are reliant on the timing of various activities, including clinical trials, being conducted by Bionomics.

Upcoming Milestones.

- BNC210 Phase 2 PTSD clinical trial data are anticipated in the second half of CY2018. Details of the trial can be found at its dedicated website <https://restorerresearchstudy.com>.
- In parallel, Bionomics is progressing potential partnership/divestment discussions and the monetisation of non-core assets.
- In addition to evaluating BNC210 partnering, we continue to evaluate opportunities to broaden the development of BNC210. Bionomics also continues to progress a number of early stage ion channel programs targeting pain, depression, cognition, PTSD and epilepsy.

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Ltd.

Deborah Rathjen
CEO & Managing Director
+61 8 8354 6100
drathjen@bionomics.com.au

Steven Lydeamore
CFO
+61 8 8354 6100
slydeamore@bionomics.com.au

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder and for post-traumatic stress disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada).

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210 and BNC101), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this announcement.

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

Bionomics Limited

ABN

53 075 582 740

Quarter ended ("current quarter")

31 March 2018

Consolidated statement of cash flows		Current quarter	Year to date (9 months)
		\$A'000	\$A'000
1	Cash flows from operating activities		
1.1	Receipts from customers	900	4,338
1.2	Payments for		
	(a) research and development	(7,257)	(17,902)
	(b) product manufacturing and operating costs	-	-
	(c) advertising and marketing	-	-
	(d) leased assets	(39)	(195)
	(e) staff costs	(601)	(1,711)
	(f) administration and corporate costs	(731)	(1,800)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	72	345
1.5	Interest and other costs of finance paid	(301)	(1,433)
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	8,115	8,115
1.8	Other (provide details if material)	-	-
1.9	Net cash from / (used in) operating activities	158	(10,243)
2	Cash flows from investing activities		
2.1	Payments to acquire:		
	(a) property, plant and equipment	-	-
	(b) businesses (see item 10)	-	-
	(c) investments	-	-
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) property, plant and equipment	-	-
	(b) businesses (see item 10)	-	-
	(c) investments	-	-
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	-	-

Appendix 4C
Quarterly report for entities subject to Listing Rule 4.7B

Consolidated statement of cash flows		Current quarter	Year to date (9 months)
		\$A'000	\$A'000
3	Cash flows from financing activities		
3.1	Proceeds from issues of shares	-	-
3.2	Proceeds from issue of convertible notes	-	-
3.3	Proceeds from exercise of share options	84	359
3.4	Transaction costs related to issues of shares, convertible notes or options	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	(627)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	84	(268)

4	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of quarter/year to date	32,021	42,875
4.2	Net cash from / (used in) operating activities (item 1.9 above)	158	(10,243)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	84	(268)
4.5	Effect of movement in exchange rates on cash held	(9)	(110)
4.6	Cash and cash equivalents at end of quarter	32,254	32,254

5	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter	Previous quarter
		\$A'000	\$A'000
5.1	Bank balances	9,754	16,789
5.2	Call deposits	22,500	15,232
5.3	Bank overdrafts		
5.4	Other (provide details)		
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	32,254	32,021

6 Payments to directors of the entity and their associates

- 6.1 Aggregate amount of payments to these parties included in item 1.2
- 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

Current quarter
\$A'000
231
-

Remuneration paid to Chief Executive Officer/Managing Director and Non-Executive Directors

Appendix 4C
Quarterly report for entities subject to Listing Rule 4.7B

7 Payments to related entities of the entity and their associates	Current quarter \$A'000
7.1 Aggregate amount of payments to these parties included in item 1.2	27
7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3	
7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	

Investor relations

8 Financing facilities available	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
<i>Add notes as necessary for an understanding of the position</i>		
8.1 Loan facilities	19,365	19,365
8.2 Credit standby arrangements		
8.3 Other (please specify)		
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		
<i>Silicon Valley Bank US\$15m, interest 8.15%, secured by substantially all of the Group's assets, other than intellectual property.</i>		

9 Estimated cash outflows for next quarter	\$A'000
9.1 Research and development	(7,067)
9.2 Product manufacturing and operating costs	-
9.3 Advertising and marketing	-
9.4 Leased assets	(59)
9.5 Staff costs	(809)
9.6 Administration and corporate costs	(908)
9.7 Other (provide details if material)	-
9.8 Total estimated cash outflows	(8,843)

10 Acquisitions and disposals of business (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1 Name of entity		
10.2 Place of incorporation or registration		
10.3 Consideration for acquisition or disposal		
10.4 Total net assets		
10.5 Nature of business		

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here: Date: 31-03-18
(Director/~~Company secretary~~)

Print name: Deborah Rathjen

Notes

- 1 The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
- 2 If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
- 3 Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.